ArticleCardiology journal2026
Adenosine and ATP differentially control osteogenic gene expression patterns in a cardiac valve cell line.
Article in Cardiology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCalcific aortic valve disease (CAVD) involves the osteogenic transition of valve interstitial cells (VICs) and is influenced by purinergic signaling. ATP is considered pro-calcific, whereas adenosine (Ado) has been reported as anti- or pro-calcific. Extracellular conversion of ATP to Ado by ecto-enzymes (including ecto-5'-nucleotidase, CD73) may shape receptor signaling in VICs. MATERIAL AND
methodsWe quantified osteogenic and apoptotic markers in the murine valve-like cell line tsA58-AVM under osteogenic conditions after treatment with ATP or Ado, selective Adora1/Adora2A agonists, and/or CD73.
resultsRunt-related transcription factor 2, isoform II (Runx2-II) expression decreased by 31% and 17% after 16 hours of exposure to 0.35 μM and 3.5 μM Ado, respectively. Adora1 activation (MeCCPA, 0.1 μM) reduced Runx2-II by 49-57% on days 1-5, and Adora2A activation (PSB0777, 1 μM) reduced Runx2-II by 17-63% at days 1-5. Repeated ATP addition (100 μM) increased osteopontin (SPP1) by 7.7- and 3.3-fold and osteocalcin (BGLAP) by 14.4- and 4.0-fold on days 5 and 12, respectively; cotreatment with CD73 (0.1 ng/μL) reduced or normalized these changes. ATP also doubled the Bcl-2- associated X protein (Bax) to B-cell lymphoma 2 protein (BCL2) ratio, an effect that was prevented by CD73.
conclusionsPurinergic ligands and receptors directly regulate VIC osteogenic differentiation and apoptosis in vitro without exogenous inflammatory stimulation. Modulation of the ATP-Ado axis may represent a therapeutic target to slow CAVD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.